SBWire

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.

Global Markets Direct's, 'Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2014', provides an overview of the Pituitary ACTH Hypersecretion (Cushing's Disease)'s therapeutic pipeline.

Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2014', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)'s therapeutic pipeline.

Global Markets Direct's, 'Metastatic Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline.

Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2014', provides an overview of the Pulmonary Arterial Hypertension's therapeutic pipeline.

GlobalData's clinical trial report, "Bone Marrow Transplantation Global Clinical Trials Review, H2, 2014" provides data on the Bone Marrow Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Marrow Transplantation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Marrow Transplantation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Circassia Pharmaceuticals plc - Product Pipeline Review - 2014', provides an overview of the Circassia Pharmaceuticals plc's pharmaceutical research and development focus.

Global Markets Direct's, 'WhanIn Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the WhanIn Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Ragweed Allergy Global Clinical Trials Review, H2, 2014" provides data on the Ragweed Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ragweed Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ragweed Allergy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2014', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2014', provides an overview of the Ovarian Cancer's therapeutic pipeline.

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2014', provides an overview of the Liver Fibrosis's therapeutic pipeline.

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)'s therapeutic pipeline.

Global Markets Direct's, 'CytImmune Sciences, Inc. - Product Pipeline Review - 2014', provides an overview of the CytImmune Sciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AngioChem Inc. - Product Pipeline Review - 2014', provides an overview of the AngioChem Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Burns - Pipeline Review, H2 2014', provides an overview of the Burns's therapeutic pipeline.

Global Markets Direct's, 'Overactive Bladder - Pipeline Review, H2 2014', provides an overview of the Overactive Bladder's therapeutic pipeline.

GlobalData's clinical trial report, "Hypersensitivity Global Clinical Trials Review, H2, 2014" provides data on the Hypersensitivity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypersensitivity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hypersensitivity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Molecular Partners AG - Product Pipeline Review - 2014', provides an overview of the Molecular Partners AG's pharmaceutical research and development focus.

Global Markets Direct's, 'TaiMed Biologics Inc. - Product Pipeline Review - 2014', provides an overview of the TaiMed Biologics Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014', provides an overview of the Amyotrophic Lateral Sclerosis's therapeutic pipeline.

Global Markets Direct's, 'Medisyn Technologies, Inc. - Product Pipeline Review - 2014', provides an overview of the Medisyn Technologies, Inc.'s pharmaceutical research and development focus.

Orphan Drug Market Access: Payer Insights on the Present and Future is a report that examines the regulation, pricing, reimbursement, players and stakeholder/payer interests that are shaping the current and future direction of the orphan drug sector.

Global Markets Direct's, 'IkerChem S.L. - Product Pipeline Review - 2014', provides an overview of the IkerChem S.L.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Pharnext SAS - Product Pipeline Review - 2014', provides an overview of the Pharnext SAS's pharmaceutical research and development focus.